$REVB: Major FDA Win: Single Study Pathway for Gemini (AKI) Approved 🚀

Ticker: REVB (Revelation Biosciences)

Sector: Biotech / Renal Health

Current Price (PM): \~$1.18 (+38% spike)

The Catalyst: Why is it moving?

Revelation Biosciences just dropped a massive PR announcing they have reached an agreement with the FDA on a simplified approval pathway for their lead candidate, Gemini, for treating Acute Kidney Injury (AKI).

The Key Takeaways from today's PR:

• Single Study NDA: The FDA agreed that a single adaptive Phase 2/3 study (approx. 300 patients) is sufficient for a New Drug Application (NDA). This cuts years and millions of dollars off the traditional "Phase 2 then Phase 3" timeline.

• Clear Endpoints: The primary endpoint is objective and high-stakes: death and/or the need for dialysis.

• Timeline: The company is now moving into "execution mode"—building trial infrastructure and engaging CROs throughout 2026.

The Financial Recap:

• Cash Position: They recently reported around $12.7M in cash, which they state is enough to carry them through Q3 2026.

• Zero Debt: Rare for a micro-cap biotech to have a clean balance sheet.

• Market Cap: Still tiny (approx. $5.5M - $7M depending on current fluctuation).

Why this matters :

1. Massive Gap to Fill: The stock has been beaten down over 90% in the last year. If this regulatory de-risking holds, the upside to previous analyst targets ($20+) is statistically wild (though obviously speculative).

2. Low Float: The float is small (\~4.4M shares), meaning high volume today could cause a significant "gamma" or momentum squeeze.

Bottom Line: This is a classic biotech "binary event" play. The FDA just gave them a green light on a much faster lane. It’s high risk, but the news is objectively a game-changer for their business model.

Disclaimer: Not financial advice. Biotech stocks are highly volatile. Do your own DD.